Diagendo

Diagendo is a leading medical device company focused on advancing women's health through innovative diagnostic solutions. Specializing in the development of cutting-edge in vitro diagnostic (IVD) medical devices, Diagendo is dedicated to improving the accuracy and efficiency of endometriosis diagnosis. Their commitment to women's health is evident in their novel approach to diagnostic testing. Located at LEŚNA, Warsaw, 05-502, Poland, Diagendo operates with a clear vision of transforming diagnostic capabilities in gynecology.

At the core of Diagendo's offerings is a real-time reverse transcription-PCR assay designed for the precise quantification of FUT4 mRNA expression, a key marker for endometriosis, relative to GAPDH reference mRNA. This advanced diagnostic test utilizes RNA isolated from endometrial biopsies during the secretory phase of the menstrual cycle, providing clinicians with critical data to confirm or exclude endometriosis. Diagendo’s work aims to minimize the diagnostic delays in this field.

With a strong foundation in medical device innovation, Diagendo continues to expand its portfolio of diagnostic tools, addressing critical needs in women's health. The team at Diagendo is driven by a passion for improving patient outcomes and enhancing the quality of healthcare through superior diagnostic technologies. We invite the manager of Diagendo to create a customized and exclusive company showcase and product listing on our platform to highlight these advancements further.